ARGNF:OTC-argenx SE (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 697.42

Change

0.00 (0.00)%

Market Cap

USD 42.54B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

+0.35 (+0.45%)

USD 33.33B
UCBJF UCB SA

N/A

USD 33.33B
GNMSF Genmab A/S

-2.29 (-1.14%)

USD 12.13B
IVBIY IVBIY

N/A

USD 10.52B
WXXWY WuXi Biologics (Cayman) Inc

-0.05 (-0.97%)

USD 10.47B
WXIBF WuXi Biologics

N/A

USD 10.43B
AKESF Akeso, Inc.

N/A

USD 9.51B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 9.09B
SBHMY Sino Biopharmaceutical Ltd ADR

+0.69 (+7.85%)

USD 9.09B
TLPPF Telix Pharmaceuticals Limited

-0.56 (-3.39%)

USD 5.56B

ETFs Containing ARGNF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.91% 66% D+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.91% 66% D+ 63% D
Trailing 12 Months  
Capital Gain 81.74% 86% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.74% 86% B+ 90% A-
Trailing 5 Years  
Capital Gain 436.47% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 436.47% 95% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 22.91% 63% D 69% C-
Dividend Return 22.91% 63% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.65% 88% B+ 75% C
Risk Adjusted Return 82.83% 99% N/A 95% A
Market Capitalization 42.54B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.